Delving into the Latest Updates on Suzhou Xinkanghe Biomedical Technology Co., Ltd. with Synapse

Overview

Tags

Skin and Musculoskeletal Diseases

Neoplasms

Immune System Diseases

Monoclonal antibody

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	2
Immune System Diseases	2
Infectious Diseases	1

Top 5 Drug Type	Count

Monoclonal antibody	4

Top 5 Target	Count

IL-25(interleukin 25)	1
B7-H4(V-set domain-containing T-cell activation inhibitor 1)	1
CD276(CD276 antigen)	1
IL-17A x IL-17F	1

Primary study objective: To evaluate the effect and safety of XKH001 injection on airway hyperresponsiveness after multiple administration in patients with allergic asthma. Secondary study objective: To evaluate the immunogenicity, PK (pharmacokinetic) characteristics and PD (pharmacodynamic) characteristics of XKH001 injection in patients with allergic asthma after multiple administration.

Start Date01 Dec 2023

Sponsor / Collaborator

Beijing Kanova Biopharmaceutical Co., Ltd.

CTR20233095 / RecruitingPhase 1

一项评价XKH002治疗晚期实体瘤患者安全性、耐受性、药代动力学的开放标签、剂量递增、多中心 Ⅰ 期临床研究

[Translation] An open-label, dose-escalation, multicenter Phase I clinical study to evaluate the safety, tolerability, and pharmacokinetics of XKH002 in the treatment of patients with advanced solid tumors

主要目的： 1. 确定XKH002治疗实体瘤患者的最大耐受剂量（MTD）或最大给药剂量（MAD），并确认扩展期推荐剂量（RDE）； 2. 评估XKH002在实体瘤患者中的安全性和耐受性。次要目的： 1. 评估XKH002的药代动力学（PK）特征； 2. 评估XKH002的抗肿瘤疗效； 3. 评估XKH002的免疫原性。探索目的： 1. 评估XKH002治疗前可溶性B7-H4及TNF-α、IFN-γ、IL-6、IL-8等其他肿瘤免疫相关因子的含量与疗效关系及治疗前后血清中含量变化； 2. 评估B7-H4、PD-L1及CD8表达水平与疗效的相关性。

[Translation]

Main objectives: 1. Determine the maximum tolerated dose (MTD) or maximum dose (MAD) of XKH002 for the treatment of patients with solid tumors, and confirm the recommended dose (RDE) for the extension phase; 2. Evaluate the safety and tolerability of XKH002 in patients with solid tumors. Secondary objectives: 1. Evaluate the pharmacokinetic (PK) characteristics of XKH002; 2. Evaluate the anti-tumor efficacy of XKH002; 3. Evaluate the immunogenicity of XKH002. Exploratory objectives: 1. Evaluate the relationship between the content of soluble B7-H4 and other tumor immune-related factors such as TNF-α, IFN-γ, IL-6, IL-8 and the efficacy before XKH002 treatment, as well as the changes in serum content before and after treatment; 2. Evaluate the correlation between the expression levels of B7-H4, PD-L1 and CD8 and the efficacy.

Start Date15 Nov 2023

Sponsor / Collaborator

Suzhou Xinkanghe Biomedical Technology Co., Ltd.

100 Clinical Results associated with Suzhou Xinkanghe Biomedical Technology Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Suzhou Xinkanghe Biomedical Technology Co., Ltd.

Login to view more data

2

Literatures (Medical) associated with Suzhou Xinkanghe Biomedical Technology Co., Ltd.

01 Mar 2020·Cellular & Molecular ImmunologyQ1 · MEDICINE

Tumor-expressed B7-H3 mediates the inhibition of antitumor T-cell functions in ovarian cancer insensitive to PD-1 blockade therapy

Q1 · MEDICINE

Article

Author: Li, Jiaming ; Guo, Li ; Xie, Shan ; Cai, Dongli ; Dong, Chen ; Hong, Shanjuan ; Sun, Tiantian ; Qiao, Qin ; Liu, Dingfeng ; Jin, Liping ; Lyu, Nanan ; Sun, Qinli ; Li, Pingping ; Ni, Ling

Although PD-L1/PD-1 blockade therapy has been approved to treat many types of cancers, the majority of patients with solid tumors do not respond well, but the underlying reason remains unclear. Here, we studied ovarian cancer (OvCa), a tumor type generally resistant to current immunotherapies, to investigate PD-1-independent immunosuppression. We found that PD-L1 was not highly expressed in the tumor microenvironment (TME) of human OvCa. Instead, B7-H3, another checkpoint molecule, was highly expressed by both tumor cells and tumor-infiltrating antigen-presenting cells (APCs), which correlated with T-cell exhaustion in patients. Using ID8 OvCa mouse models, we found that B7-H3 expressed on tumor cells, but not host cells, had a dominant role in suppressing antitumor immunity. Therapeutically, B7-H3 blockade, but not PD-1 blockade, prolonged the survival of ID8 tumor-bearing mice. Collectively, our results demonstrate that tumor-expressed B7-H3 inhibits the function of CD8⁺ T cells and suggest that B7-H3 may be a target in patients who are not responsive to PD-L1/PD-1 inhibition, particularly OvCa patients.

Frontiers in OncologyQ3 · MEDICINE

Establishment of an Ex Vivo Tissue Culture Model for Evaluation of Antitumor Efficacy in Clear Cell Renal Cell Carcinoma

Q3 · MEDICINE

ArticleOA

Author: Hong, Shanjuan ; Guo, Li ; Dou, Yuan ; Ni, Ling ; Lu, Jian ; Xie, Tian ; Zhang, Zhiyin ; Dong, Chen ; Yuan, Qing ; Sun, Tiantian ; Xia, Haizhui ; He, Wei

There are many potential immunotherapeutic targets for cancer immunotherapy, which should be assessed for efficacy before they enter clinical trials. Here we established an ex vivo cultured patient-derived tumor tissue model to evaluate antitumor effectiveness of one VISTA inhibitor, given that our previous study showed that VISTA was selectively highly expressed in human clear cell renal cell carcinoma (ccRCC) tumors. We observed that all the tested patients responded to the anti-VISTA monoclonal antibody as manifested by TNF-α production, but only a small fraction were responders to the anti-PD-1 antibody. Co-blockade of VISTA and PD-1 resulted in a synergistic effect in 20% of RCC patients. Taken together, these findings indicate that this ex vivo tumor slice culture model represents a viable tool to evaluate antitumor efficacies for the inhibitors of immune checkpoints and further supports that VISTA could serve as a promising target for immunotherapy in ccRCC.

100 Deals associated with Suzhou Xinkanghe Biomedical Technology Co., Ltd.

Login to view more data

100 Translational Medicine associated with Suzhou Xinkanghe Biomedical Technology Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

1

Phase 1 Clinical

Phase 2 Clinical

1

Phase 3 Clinical

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Recombinant human IL-17A/F humanized antibody(Livzon Pharmaceutical Group) ( IL-17A x IL-17F )	Plaque psoriasis More	Phase 3
XKH-001 ( IL-25 )	Asthma More	Phase 2 Clinical
XKH-002 ( B7-H4 )	Advanced Malignant Solid Neoplasm More	Phase 1
XKH-007 ( CD276 )	Neoplasms More	Preclinical